Digest Network Come funziona
Network
/
Società
Sh
Non verificato

Shionogi USA

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieSaluteScienza

10 comunicati stampa

Guarda tutti i comunicati
22/12/2025
Igiene alimentare
Salute
Scienza
Farmaceutica
Biotecnologia
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
20/10/2025
Salute
Scienza
Sanità
Farmaceutica
Biotecnologia
Eventi
IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
03/09/2025
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Eventi
Fiere
Industria
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
02/09/2025
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Industria
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
12/03/2025
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
04/02/2025
Scienza
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Mercato del lavoro
Industria
Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
16/01/2025
Eventi
Mercato del lavoro
Industria
Scienza
Sanità
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
16/10/2024
Eventi
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously Ill Patients
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
04/09/2024
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentations from Its Expanding Product Portfolio at IDWeek 2024
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0
18/07/2024
Scienza
Sanità
Famiglia
Farmaceutica
Vetrine/Shopping
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
Eventi
Industria
Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Including Recent Changes to Study Protocol to Increase Access for Participants and Families
Fonte
Shionogi USA
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0